AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX109.05+2.61 (+2.45%) ▲|SCHW92.26-0.69 (-0.74%) ▼|SO94.01+1.17 (+1.26%) ▲|SPG234.13+1.12 (+0.48%) ▲|T22.51+0.32 (+1.44%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN293.14-10.46 (-3.45%) ▼|UBER69.62-0.05 (-0.06%) ▼|UNH414.32+6.71 (+1.65%) ▲|UNP304.08+1.63 (+0.54%) ▲|UPS110.81+0.02 (+0.02%) ▲|USB60.97-0.03 (-0.04%) ▼|V429.80+3.72 (+0.87%) ▲|VZ46.93+0.56 (+1.21%) ▲|WFC86.10+0.06 (+0.06%) ▲|WMT129.53+1.44 (+1.12%) ▲|XOM167.96-1.65 (-0.97%) ▼|AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX109.05+2.61 (+2.45%) ▲|SCHW92.26-0.69 (-0.74%) ▼|SO94.01+1.17 (+1.26%) ▲|SPG234.13+1.12 (+0.48%) ▲|T22.51+0.32 (+1.44%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN293.14-10.46 (-3.45%) ▼|UBER69.62-0.05 (-0.06%) ▼|UNH414.32+6.71 (+1.65%) ▲|UNP304.08+1.63 (+0.54%) ▲|UPS110.81+0.02 (+0.02%) ▲|USB60.97-0.03 (-0.04%) ▼|V429.80+3.72 (+0.87%) ▲|VZ46.93+0.56 (+1.21%) ▲|WFC86.10+0.06 (+0.06%) ▲|WMT129.53+1.44 (+1.12%) ▲|XOM167.96-1.65 (-0.97%) ▼|
6 C
New York
Monday, November 16, 2026
Press ReleasesHealth CareJeonbuk National University Team Develops Dual-Action Bacterial Cancer Therapy

Jeonbuk National University Team Develops Dual-Action Bacterial Cancer Therapy

Researchers engineered bacteria carrying two anticancer payloads and tested their effects in mouse breast cancer models

JEONJU-SI, South Korea, Nov. 16, 2026 /PRNewswire/ — Tumors that resist immune attack, recur, and spread pose a major challenge to cancer treatment. Because certain bacteria naturally accumulate within tumors, they serve as potential carriers for anticancer agents. Addressing this, a research team from the Republic of Korea—led by Professor John Hwa Lee from the Laboratory of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University—developed an engineered strain of Salmonella Typhimurium carrying two anticancer components.

The team deleted the trpA, trpE, asd, and pagL genes to attenuate the bacterium and make it dependent on tryptophan, then passaged it in tumor-bearing mice to improve tumor localization. The resulting strain, JOL3136, carried a dual-expression plasmid designed to produce apoptin inside cancer cells and a carcinoembryonic antigen (CEA) epitope protein in the bacterial compartment. The team confirmed apoptin expression at 18 kDa and CEA epitope expression at 27 kDa. This paper was made available online on August 6, 2026, and was published in Volume 202 of the journal Biomedicine & Pharmacotherapy on September 1, 2026.

The team tested the engineered bacteria using 4T1 cells, a highly metastatic mouse breast cancer cell line. Compared with untreated cells and bacterial-vector controls, JOL3136-treated cells showed greater early and late apoptosis. Mice bearing 4T1 tumors received four weekly doses of a control solution, the bacterial vector, or JOL3136. The therapeutic strain significantly reduced tumor mass and volume compared with both control groups. Tumor-volume reduction in the JOL3136 group was reported to exceed that of the vector-control group by more than 200%.

The researchers also examined immune activity and cancer-cell spread. JOL3136 treatment was associated with increased CD49b-positive lymphocytes and interferon-gamma (IFN-γ), alongside changes in immune cells within the tumor. In a separate metastasis experiment, labeled cancer cells detected in the lungs, liver, and spleen were significantly fewer in JOL3136-treated mice than in control mice.

“Cancer treatment needs ways to reach tumors while also addressing the immune environment that can help them persist,” said Prof. Lee. “Our approach combines a bacterial delivery vehicle with apoptin to promote cancer-cell death and CEA epitopes to stimulate antitumor immunity.” The findings point to a strategy that may act through direct effects on cancer cells and changes in immune activity. However, the study did not establish the separate contribution of each component.

“An important feature of this platform is that the bacterial carrier can be modified to deliver other therapeutic candidates,” said Prof. Lee. “Before clinical use can be considered, we need stronger safety safeguards and further evaluation in models that better represent human disease.” Live Salmonella-based treatments require stringent measures to reduce infection risks and testing to determine how the bacterial carrier and each payload contribute to the effects.

This platform offers a compelling proof-of-concept for tackling aggressive breast cancer through combined tumor destruction and immune activation. However, these results are limited to mouse models and do not translate to clinical use yet. Moving forward, researchers will need to evaluate the therapy in human-relevant settings, tighten biosafety protocols, and dissect the independent contributions of the bacterial carrier, apoptin, and the targeted antigen.

Reference

Title of original paper: Therapeutic Salmonella expressing apoptin and CEA elicits combined pro-apoptotic and immune-mediated anticancer effects

Journal: Biomedicine & Pharmacotherapy

DOI: 10.1016/j.biopha.2026.119840

About Jeonbuk National University 

Website: https://www.jbnu.ac.kr/en/index.do

Contact:

Sang-Duk Her

82 63 270 4638

426997@email4pr.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jeonbuk-national-university-team-develops-dual-action-bacterial-cancer-therapy-302938987.html

SOURCE Jeonbuk National University

Recent News